Rheumatology Advance Access originally published online on May 18, 2004
Rheumatology 2004 43(8):943-945; doi:10.1093/rheumatology/keh217
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rheumatology Vol. 43 No. 8 © British Society for Rheumatology 2004; all rights reserved
Editorial |
Atherosclerosis and lupus
Centre for Rheumatology, Department of Medicine, University College London, London, UK
Correspondence to: D. Isenberg, Centre for Rheumatology, Department of Medicine, University College London, Arthur Stanley House, 4050 Tottenham Street, London W1T 4NJ, UK.
| The first 150 words of the full text of this article appear below. |
As we write this editorial, snow flurries are swirling around the country. Falling snow restricts visibility but once settled and on a clear day the bright reflected light often seems to increase visual acuity. By analogy, we will explore whether a recent flurry of papers on atherosclerosis in patients with systemic lupus erythematosus (SLE) has helped to shed light on this challenging clinical problem or whether we are still stuck in a period of reduced visibility.
Attention was first drawn to the increased risk of atherosclerosis and, in particular, death due to atherosclerosis in patients with SLE by Murray Urowitz and his colleagues in 1976 [1]. Subsequent studies have confirmed these findings, with reports of up to 30% of deaths in SLE patients being due to coronary artery disease [2, 3]. Despite the fact that survival has improved significantly over the past 50 yr, SLE
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
C Nannini, C. Crowson, E. Matteson, and K. Moder Mycophenolate mofetil is effective in reducing disease flares in systemic lupus erythematosus patients: a retrospective study Lupus, April 1, 2009; 18(5): 394 - 399. [Abstract] [PDF] |
||||
